Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
12.54B
Market cap12.54B
Price-Earnings ratio
15.82
Price-Earnings ratio15.82
Dividend yield
Dividend yield
Average volume
3.40M
Average volume3.40M
High today
$51.14
High today$51.14
Low today
$49.97
Low today$49.97
Open price
$50.55
Open price$50.55
Volume
1.86M
Volume1.86M
52 Week high
$57.57
52 Week high$57.57
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $50.66. The company's market cap stands at 12.54B, with a P/E ratio of 15.82.

On 2026-08-13, Exelixis(EXEL) stock traded between a low of $49.97 and a high of $51.14. Shares are currently priced at $50.66, which is +1.4% above the low and -0.9% below the high.

The Exelixis(EXEL)'s current trading volume is 1.86M, compared to an average daily volume of 3.4M.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $57.57 and a 52-week low of $33.76.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $57.57 and a 52-week low of $33.76.

EXEL News

Investing.com 23h
Exelixis director Mary Beckerle sells $526k in shares - Investing.com

...

Exelixis director Mary Beckerle sells $526k in shares - Investing.com
The Motley Fool 24h
Exelixis Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, Aug. 5, 2026 at 5:00 p.m. ET CALL PARTICIPANTS President - Michael Morrissey Chief Financial Officer - Christopher Se...

Exelixis Q2 2026 Earnings Call Transcript
Simply Wall St 2d
Exelixis Earnings Strength Meets Lower Guidance As Valuation Comes Back Into View

Exelixis (EXEL) is back in focus after reporting second quarter results that showed higher revenue and net income year on year, while also trimming full year re...

Exelixis Earnings Strength Meets Lower Guidance As Valuation Comes Back Into View

Analyst ratings

57%

of 21 ratings
Buy
33.3%
Hold
57.1%
Sell
9.5%

More EXEL News

TipRanks 6d
Exelixis Earnings Call: Cabo Strength, Zanza Awaited

Exelixis ((EXEL)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with TipRan...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.